Lyra Therapeutics (LYRA) News Today $10.44 -0.24 (-2.20%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYRA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated CatalystJune 16, 2025 | seekingalpha.comHC Wainwright Issues Positive Outlook for LYRA EarningsJune 13, 2025 | americanbankingnews.comH.C. Wainwright lifts Lyra Therapeutics stock target to $16June 12, 2025 | investing.comLyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in ...June 4, 2025 | seekingalpha.comLyra Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:LYRA | BenzingaJune 3, 2025 | benzinga.comLyra Therapeutics (NASDAQ:LYRA) Stock, Insider Trading ActivityJune 3, 2025 | benzinga.comLyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s ThrilledJune 2, 2025 | msn.comWall Street drifts higher as oil prices jump and US manufacturing slumpsJune 2, 2025 | msn.comLyra Therapeutics Shares Skyrocket on Strong Phase 3 Results for CRS TreatmentJune 2, 2025 | msn.comLyra Therapeutics Shares Climb Over 500% After Major CRS Trial WinJune 2, 2025 | finance.yahoo.comWhy Is Lyra Therapeutics Stock Surging Over 400% On Monday?June 2, 2025 | benzinga.comLyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)June 2, 2025 | globenewswire.comLyra Therapeutics, Inc. (NASDAQ:LYRA) Sees Large Decrease in Short InterestLyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) was the recipient of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 146,600 shares, a decrease of 94.6% from the April 30th total of 2,700,000 shares. Based on an average daily trading volume, of 63,800 shares, the short-interest ratio is presently 2.3 days. Currently, 13.1% of the shares of the company are short sold.May 30, 2025 | marketbeat.comLyra Therapeutics trading halted, news pendingMay 28, 2025 | msn.comLyra Therapeutics Reports Q1 2025 Financial ResultsMay 14, 2025 | tipranks.comLyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025May 7, 2025 | globenewswire.comLyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comLyra Therapeutics Reports 2024 Financial Results and UpdatesMarch 15, 2025 | tipranks.comLyra Therapeutics (LYRA) Gets a Hold from William BlairMarch 14, 2025 | markets.businessinsider.comLyra Therapeutics reports Q4 EPS ($1.43), consensus (13c)March 13, 2025 | markets.businessinsider.comLyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 13, 2025 | globenewswire.comZevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue EstimatesMarch 11, 2025 | msn.comLyra Therapeutics Pursues ENLIGHTEN 2 Trial for LYR-210January 10, 2025 | markets.businessinsider.comLyra Therapeutics: Hold Rating Due to Uncertainty in ENLIGHTEN-2 Trial OutcomesNovember 15, 2024 | markets.businessinsider.comLyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagNovember 15, 2024 | finance.yahoo.comLyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | globenewswire.comLyra Therapeutics, Inc. (LYRA)October 22, 2024 | finance.yahoo.comLyra Therapeutics completes Phase 3 trial enrollment for CRS treatmentOctober 17, 2024 | uk.investing.comLyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic RhinosinusitisOctober 15, 2024 | globenewswire.comLyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual MeetingsSeptember 27, 2024 | globenewswire.comLyra Therapeutics Insiders Still US$66k Away From Original Investment ValueAugust 22, 2024 | uk.finance.yahoo.comLyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | globenewswire.comCeltic academy graduate Lawal makes permanent switch to StokeAugust 12, 2024 | bbc.comLyra Therapeutics, Inc. (LYRA) latest stock news & headlines – Yahoo FinanceJuly 19, 2024 | nz.finance.yahoo.comLyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1?July 15, 2024 | insidermonkey.comMaintaining Hold on ProKidney: Balancing Market Potential Against Clinical UncertaintiesMay 29, 2024 | markets.businessinsider.comLyra to cut 75% of workforce in portfolio shakeupMay 21, 2024 | msn.comLyra Therapeutics Announces Cost-Cutting Measures to Preserve CapitalMay 21, 2024 | globenewswire.comTarget upgraded, CVS downgraded: Wall Street's top analyst callsMay 15, 2024 | finance.yahoo.comHold Rating on Lyra Therapeutics Amid Clinical Trial Setbacks and Financial UncertaintiesMay 7, 2024 | markets.businessinsider.comBTIG Downgrades Lyra Therapeutics (LYRA)May 7, 2024 | msn.comWhere Lyra Therapeutics Stands With AnalystsMay 7, 2024 | markets.businessinsider.comLyra Therapeutics (NASDAQ:LYRA) Cut to "Neutral" at HC WainwrightHC Wainwright downgraded shares of Lyra Therapeutics from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $12.00 to $2.00 in a research report on Tuesday.May 7, 2024 | marketbeat.comWhy Lyra Therapeutics Stock Is Down 93% TodayMay 6, 2024 | msn.comLyra Therapeutics's Phase 3 Enlighten Trial 1 Fails To Meet Primary Endpoint; Stock DownMay 6, 2024 | markets.businessinsider.comLyra Therapeutics Shares Plummet 90% After Chronic Rhinosinusitis Drug Fails in StudyMay 6, 2024 | marketwatch.comTrading was temporarily halted for "LYRA" at 12:05 PM with a stated reason of "LULD pause." Trading set to resume at 12:05 PM. May 6, 2024 | marketbeat.comWhy Is Lyra Therapeutics (LYRA) Stock Down 90% Today?May 6, 2024 | investorplace.comLyra Therapeutics Lead Drug Candidate Fails in Phase 3 StudyMay 6, 2024 | marketwatch.comLyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic RhinosinusitisMay 6, 2024 | globenewswire.com Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address LYRA Media Mentions By Week LYRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LYRA News Sentiment▼1.280.68▲Average Medical News Sentiment LYRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LYRA Articles This Week▼20▲LYRA Articles Average Week Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HYPR News Today SURG News Today CTCX News Today ICCM News Today MDAI News Today APT News Today SPAI News Today DXR News Today MODD News Today ECOR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LYRA) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhat a “Mar-a-Lago Accord” could mean for the US dollar.25-Year Market Vet Issues Urgent Dollar Warning He's spent 25 years tracking the flow of global money - now...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredTrump Makes Major Crypto AnnouncementTrump's crypto revolution is now fully underway and now, we believe he’s about to deliver on his biggest promi...Crypto 101 Media | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredGold Just Jumped Again. Here’s How to Get PaidGold prices just spiked again. As I write this, gold is trading near $3,400 an ounce. But here's the thi...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LYRA Stock Free LYRA Stock Alerts